Vitamin E treatment for children with chronic hepatitis B: A randomized placebo controlled trial
| Autor: | Hans-Georg Posselt, Robert van Gemmern, Patrick Gerner, Matthias Zense, Albina Innerhofer, Stefan Wirth, Ariadne Hector, Rüdiger Adam, Andreas Krahl, Tobias G. Wenzl, Gerhard Dockter, Martin Claßen, Jenny Neubert, Antje Ballauff, Christa Binder |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Hepatitis B virus medicine.medical_specialty medicine.medical_treatment Placebo-controlled study Placebo medicine.disease_cause Gastroenterology Antioxidants law.invention Hepatitis B Chronic Double-Blind Method Randomized controlled trial law Internal medicine medicine Humans Vitamin E Hepatitis B e Antigens Prospective Studies Child Transaminases Dose-Response Relationship Drug business.industry Lamivudine General Medicine Hepatitis B medicine.disease Treatment Outcome HBeAg DNA Viral Immunology Female business Rapid Communication Follow-Up Studies medicine.drug |
| Zdroj: | World Journal of Gastroenterology. 14:7208 |
| ISSN: | 1007-9327 |
| Popis: | AIM: To evaluate the safety and efficacy of vitamin E in children with chronic hepatitis B. METHODS: We randomly assigned patients with chronic hepatitis B, positive for hepatitis B e antigen (HBeAg), to receive either vitamin E or placebo once daily for 6 mo in a 3:1 ratio and double-blind manner. The primary end point was HBeAg seroconversion, defined as the loss of HBeAg, undetectable levels of serum hepatitis B virus DNA, and the appearance of antibodies against HBeAg 12 mo after therapy. RESULTS: At baseline visit, 49 patients had normal and 43 had increased serum aminotransferase levels. Twenty-nine patients did not respond to previous treatment with interferon-α or lamivudine. Seventy-six children completed the study; 16 were non-compliant (n = 7), lost to follow-up (n = 7), or started another antiviral treatment (n = 3). Intention-to-treat analysis showed HBeAg seroconversion in 16 children (23.2%) treated with vitamin E and two (8.7%) in the placebo group (P = 0.13). Vitamin E was well tolerated. CONCLUSION: There is only a tendency that vitamin E may promote HBeAg seroconversion. Therefore larger studies are needed to clarify the role of antioxidants in the therapy of chronic hepatitis B. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|